Cargando…
Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)
There are substantial disease and health-related quality-of-life (HRQoL) burdens for many patients with myasthenia gravis (MG), especially for those whose disease symptoms are not well controlled. HRQoL measures such as the Myasthenia Gravis Quality of Life 15-item revised (MG-QOL15r) and EuroQoL 5-...
Autores principales: | Saccà, Francesco, Barnett, Carolina, Vu, Tuan, Peric, Stojan, Phillips, Glenn A., Zhao, Sihui, Qi, Cynthia Z., Gelinas, Deborah, Chiroli, Silvia, Verschuuren, Jan J. G. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025199/ https://www.ncbi.nlm.nih.gov/pubmed/36598575 http://dx.doi.org/10.1007/s00415-022-11517-w |
Ejemplares similares
-
A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021) -
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023) -
Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023) -
Association Between Myasthenia Gravis–Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities
por: Dewilde, Sarah, et al.
Publicado: (2023) -
Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale
por: Barnett, Carolina, et al.
Publicado: (2015)